Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel +/- Vandetanib in Recurrent Ovarian Cancer
NCT00872989Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Mar 2010
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vandetanib in ovarian epithelial cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by SWOG Cancer Research Network. Primary endpoint: Progression-Free Survival up to 5 years. Started Mar 2010; status: completed.
02
Drugs
vandetanib
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00872989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00872989.